advanced
Biomedical Letters ISSN 2410-955X
2017 | Volume 3 | Issue 2 | Pages 131-133
Copyright © 2013-2017
The Science Publishers. All Rights Reserved.

Home        Journals         Books        Join Us          Contact Us        Terms & Conditions
Case report
Pyoderma Gangrenosum associated with type 1 Diabetes Mellitus: A Case Report 
Muhammad Ahmed Javed 1, Muhammad Arif Anwar 2, Khawar Ali Shahzad 3, Santha Kumar Krishnagopalan 4, Eman Jasim Mohamed Saleh Alsaffar 1, Noor Sultan 5, Jin Hui 1*

1 Department of Endocrinology, Zhongda Hospital, Southeast University, Nanjing, China.
Department of Cardiology, The Affiliated Zhongda Hospital of Southeast University, No. 87 Dingjiaqiao, Nanjing, China
3 Department of Microbiology and Immunology, Medical School, Southeast University, Nanjing, China.
4 Department of Dermatology, Gulou Hospital, Nanjing, China.
5 Department of Public Health, Medical School, Southeast University, Nanjing, China.

Abstract
Pyoderma gangrenosum is a very rare non-infectious leukocytic dermatosis which is found to be associated with autoimmune disease process such as diabetes mellitus type I, resulting in compromised insulin production. The ulcers of pyoderma gangrenosum are mostly found at the surgical sites. Mostly, the oral and parenteral steroids (prednisolone and dexamethasone) and immunosuppressive agents such as cyclosporine are used as its first line of treatment. Herein, we report a case of pyoderma gangrenosum in a 24 years old Chinese (Han race) female who was presented with a skin infection that developed 10 days earlier and had a history of diabetes mellitus (type 1). The patient was already using insulin to control the hyperglycemia. Pyoderma is a very rare surgical complication that can only be treated successfully by corticosteroids and anti-bacterial agents. To the best of our knowledge, this is the first case report of pyoderma that has been associated with diabetes mellitus (type I).
Keywords: pyoderma gangrenosum, diabetes mellitus type I, dermatosis, corticosteroid, autoimmune disease. 

Received September 11, 2017;         Revised October 30, 2017;         Accepted November 25, 2017    
*Correspondence: Jin Hui         Email: jinhuison@126.com,         Contact: +86-25-83262811